Navigation Links
Carnegie Mellon scientists find key HIV protein makes cell membranes bend more easily

PITTSBURGH -- Carnegie Mellon University scientists have made an important discovery that aids the understanding of why HIV enters immune cells with ease. The researchers found that after HIV docks onto a host cell, it dramatically lowers the energy required for a cell membrane to bend, making it easier for the virus to infect immune cells. The finding, in press in Biophysical Journal, will provide vital data to conduct future computer simulations of HIV dynamics to help further drug discovery and prevent deadly infections.

“We found that HIV fusion peptide dramatically decreases the amount of energy needed to bend a cell-like membrane,” said Stephanie Tristram-Nagle, associate research professor of biological physics at Carnegie Mellon. “This helps membranes to curve, a necessary step for HIV to fuse with an immune cell as it infects it.”

The Carnegie Mellon scientists used X-rays to study how HIV fusion peptide (part of a larger protein) affected the energy of manufactured lipid bilayers made to mimic normal cell membranes. Lipid bilayers provide a protective barrier for the cell against intruders, yet also contain molecules to recognize and communicate with other cells or get nutrients. Cells also communicate with one another via small, membrane-bound vesicles that contain proteins or other molecular cargo. When delivering their goods, vesicles from one cell fuse with the outermost membrane of another cell to form a series of hybrid structures called fusion intermediates.

Through evolution, viruses have also become skilled at fusing with cells to unload their genetic contents, which turn host cells into virus-producing factories. In the case of HIV, a molecule called gp120 initially helps the virus lock onto its host T cell, a cell critical for maintaining immunity. Another protein — gp41 — then enables HIV to penetrate a T-cell membrane. Fusion takes place specifically through a short stretch of gp41 called fusion peptide 23, or FP-23 for short
'"/>

Source:Carnegie Mellon University


Page: 1 2 3

Related biology news :

1. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
2. Robot-based system developed at Carnegie Mellon detects life in Chiles Atacama desert
3. Green catalyst destroys pesticides and munitions toxins, finds Carnegie Mellon University
4. Carnegie Mellon University research reveals how cells process large genes
5. Carnegie Mellon cyLab researchers work to develop new red tide monitoring
6. Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace
7. Carnegie Mellon scientists create PNA molecule with potential to build nanodevices
8. Carnegie Mellon U. transforms DNA microarrays with standard Internet communications tool
9. Carnegie Mellon develops non-invasive technique to detect transplant rejection at cellular level
10. Carnegie Mellon scientists show brain uses optimal code for sound
11. DNA conclusive yet still controversial, Carnegie Mellon professor says

Post Your Comments:
(Date:11/19/2009)...ists are revealing the genetic instructions inside... maize, has one of the most complex sequences of D...ison genomicist David Schwartz, who was one of mor...Science . , "The maize genome is a true maze fu...oubled would-be sequencers for years," says Schwar...
(Date:11/19/2009)... 1 = more than 2: The offspring of two inbred stra...Characterizing the gene-level variability that lea...d vigor, could boost our ability to custom-tailor ...ntent for human consumption or high glucose conten...released DNA sequence of the common corn strain B7...
(Date:11/19/2009)...etic diversity in maize, also known as corn, resea...gene map that should pave the way to significant i...ood, fuel, animal feed and fiber around the world.... as a haplotype map, charts genetic diversity and ... of maize. The research team, led by U.S. Departme...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President International Sales 5593 1University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President International Sales 5593 2University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President International Sales 5593 3BrainCells Inc Broadens Scientific Advisory Board Adding Drs Edward Scolnick and David Holtzman 5590 1BrainCells Inc Broadens Scientific Advisory Board Adding Drs Edward Scolnick and David Holtzman 5590 2BrainCells Inc Broadens Scientific Advisory Board Adding Drs Edward Scolnick and David Holtzman 5590 3Enhanced Food Safety and Systems Interoperability the Themes of Food Traceability Interoperability Summit 2010 5587 1Enhanced Food Safety and Systems Interoperability the Themes of Food Traceability Interoperability Summit 2010 5587 2
...ns when no medical necessity exists - Florida, Ne...ington, Florida increase most , The number of pre...sarean section (C-section) rose by 36.6 percent fr...ay by HealthGrades, the leading provider of indepe...e variation from state to state in the rate of the...
...al waste, placental tissue could feasibly provide ...l to treat diseases and regenerate tissues as thei...cells, suggests a University of Pittsburgh study t...able now as an early online publication in Stem Ce...mnion, or the outer membrane of the amniotic sac, ...
... the risk of mother-to-child transmission of hepat...ublished in the December 1 issue of The Journal of... study found that infant girls are twice as likely...ide new information with which to counsel pregnant...new studies expand upon preliminary data from smal...
Other Biology News:'Patient-choice' C-section rate rises 36%: HealthGrades study 2'Patient-choice' C-section rate rises 36%: HealthGrades study 3Discarded placentas deliver researchers promising cells similar to embryonic stem cells 2Discarded placentas deliver researchers promising cells similar to embryonic stem cells 3Discarded placentas deliver researchers promising cells similar to embryonic stem cells 4Studies clarify risk factors for mother-to-child transmission of hepatitis C virus 2
(Date:11/18/2009)... -- Marrone Bio Innovations (MBI), a leader in the...ffective and environmentally responsible pest mana...an IC20 company by the Investors, Circle, the Unit...ting group. ,, Companies named to the IC20 exce...all stakeholders, including investors, the environ...
(Date:11/18/2009)...ind explosive materials and persons who have been ...tional Institute of Standards and Technology (NIST...curity, has developed a new certified reference ma...ace Particulate Explosives. Compatible with field ...ful in calibrating, testing and developing standar...
(Date:11/18/2009)...e developing new sensors to detect chemical agents...ainst the threat of terrorist attacks. , The dev...idual or crime scene to gather a sample which is t...ect the presence of chemicals within seconds. This... response to terrorist threats. , The scanning ...
(Date:11/18/2009)...alysis combined with Bio-Rad,s Biotechnology E...ovide state-of-the-art solutions to biotechnology ...wire/ -- Vernier Software & Technology, a prov...nd software and Bio-Rad Laboratories, Inc., a mult...ence research and clinical diagnostics products th...
Breaking Biology Technology:Marrone Bio Innovations Named an IC20 Company 2New NIST trace explosives standard slated for homeland security duty 2New technology detects chemical weapons in seconds 2Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2
...ce to $0.64 - $0.67 from Prior Range of ... EPS Guidance of $0.90 - $1.10 for 2009 and $1.50 ...PITTSBURGH, Oct. 30 Mylan Inc. (NYSE: MYL ),toda...d nine months ended,Sept. 30, 2008., Financial Hi....52 for the three and nine,months ended Sept. 30, ...
...Inc. (Nasdaq:,INSM), a developer of follow-on biol...ts for the third quarter and nine-months ended Sep... Follow-on Biologics Program -- Received app... Healthcare products Regulatory Agency to init...pany,s second follow-on biologic ("FOB") ...
...oratories Inc., a,specialty pharmaceutical and dia...nd Trademark Office (USPTO) has issued two separat...) Thiopurine Metabolites, a,diagnostic test that e...iopurines to reach and maintain desired therapeuti...he claims in U.S. Patent Nos. 7,425,546 and,7,429,...
Other Biology Technology:Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 2Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 4Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 5Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 6Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 7Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 8Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 9Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 10Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 12Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 13Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 14Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 2Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 3Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 4Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 5Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 6Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 7Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 8Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 9Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008 10Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing 2
...Kit contains all reagents necessary to efficiently...tic lineage, as determined by staining for mineral...essary reagents and a protocol for quantifying ost...uct is useful for studying the effects of growth f...
...arch: Developed for a wide range of bioanalytical ... in Luminescence Spectroscopy • Automated acc...ic gratings for reduced stray light • Versati...non lamp reduces photo bleaching • Large conv...
...tent-pending Formula Predictor software takes adva... pattern verification, and unique fragment-ion fil...ect formula for unknown components. Traditional ...ss spec data often depend on very high mass accura...
PerkinElmer Spectrum Beer's Law QUANT Quantitative Software, Floppy Disk from PerkinElmer
Biology Products: